An intravitreal insert provides durable control of multiple retinal diseases, according to a presentation at Retina World ...

RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients ...

Please provide your email address to receive an email when new articles are posted on . Patients with inherited retinal diseases may present with seemingly routine conditions. Look for comorbid ...

Retinal diseases are at the forefront of a quiet revolution in the realm of ophthalmology. Gene therapy, once a distant dream, is now emerging as a beacon of hope for millions affected by these ...

Nanoscope Therapeutics Inc., a biotechnology company focused on developing and commercializing novel, disease‑agnostic therapies for patients with photoreceptor loss and vision impairment due to ...

Nationwide survey finds nearly half of people with inherited retinal disease waited more than five years for genetic ...

Researchers at the University of Oklahoma are advancing the fight against inherited retinal diseases (IRDs) with new genetic research that aims to improve diagnoses and lay the groundwork for future ...

VEGF biosimilar has moved closer to European approval for several vision-threatening retinal diseases, including choroidal neovascularization.

Sunir Garg, MD, expresses excitement about attending AAO 2025 and focuses on several topics to be discussed. These include the benefits and potential vision risks of GLP-1 inhibitors in patients with ...

An AI segmentation system was able to identify changes in retinal segmented features based on optical coherence tomography (OCT) images. Diagnosing and monitoring retinal diseases is done through OCT, ...

For those with a rare retinal disease called MacTel, there is now an implant that can help them hold onto their independence ...

This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.